The country’s leading research and development-driven pharmaceutical company, Venus Remedies Limited (VRL), registered a 61 per cent growth in annual sales in 2020-21 over the previous financial year, meeting large export orders despite constraints arising out of COVID-19. is of.
During this period, the company’s growth journey has been driven by two key pillars – one, strong supply of pharmaceutical ingredients from long-standing key suppliers, and two, increased exports globally. Based on these key growth drivers, VRL’s annual sales increased from Rs 339.33 crore in FY 2019-20 to Rs 548.12 crore in this fiscal.
Initiating a debt-free future for the company, VRL has repaid its entire debt with banks and financial institutions in the financial year 2020-21.